Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00039910
Status:
COMPLETED
Last Update Posted:
2007-05-04
First Post:
2002-06-14
Brief Title:
Safety and Efficacy of PN-152243PN-196444 in the Prevention of Thrombocytopenia
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Safety and Efficacy of PN-152243PN-196444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitts Non-Hodgkins Lymphoma NHL or Hodgkins Disease Receiving DHAP Dexamethasone High-Dose Cytarabine and Cisplatin Chemotherapy
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Intensive chemotherapy is associated with significant thrombocytopenia often requiring platelet transfusion to maintain platelet counts This investigational drug has been demonstrated to increase platelet counts This study will test the safety and efficacy of the investigational drug in the prevention of thrombocytopenia in patients with recurrent or refractory intermediate-grade or high-grade non-Burkitts non-Hodgkins lymphoma NHL or Hodgkins disease receiving DHAP Dexamethasone high-dose Cytarabine and Cisplatin chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None